AIMS: The aim of this study was to quantify the collective effect of common lipid-associated single nucleotide polymorphisms (SNPs) on blood lipid levels, cardiovascular risk, use of lipid-lowering medication, and risk of coronary heart disease (CHD) events. METHODS AND RESULTS: Analysis was performed in two prospective cohorts: Whitehall II (WHII; N = 5059) and the British Women's Heart and Health Study (BWHHS; N = 3414). For each participant, scores were calculated based on the cumulative effect of multiple genetic variants influencing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Compared with the bottom quintile, individuals in the top quintile of the LDL-C genetic score distribution had higher LDL-C {mean difference of 0.85 [95% confidence interval, (CI) = 0.76-0.94] and 0.63 [95% CI = 0.50-0.76] mmol/l in WHII and BWHHS, respectively}. They also tended to have greater odds of having 'high-risk' status (Framingham 10-year cardiovascular disease risk >20%) [WHII: odds ratio (OR) = 1.36 (0.93-1.98), BWHHS: OR = 1.49 (1.14-1.94)]; receiving lipid-lowering treatment [WHII: OR = 2.38 (1.57-3.59), BWHHS: OR = 2.24 (1.52-3.29)]; and CHD events [WHII: OR = 1.43 (1.02-2.00), BWHHS: OR = 1.31 (0.99-1.72)]. Similar associations were observed for the TC score in both studies. The TG score was associated with high-risk status and medication use in both studies. Neither HDL nor TG scores were associated with the risk of coronary events. The genetic scores did not improve discrimination over the Framingham risk score. CONCLUSION: At the population level, common SNPs associated with LDL-C and TC contribute to blood lipid variation, cardiovascular risk, use of lipid-lowering medications and coronary events. However, their effects are too small to discriminate future lipid-lowering medication requirements or coronary events.
AIMS: The aim of this study was to quantify the collective effect of common lipid-associated single nucleotide polymorphisms (SNPs) on blood lipid levels, cardiovascular risk, use of lipid-lowering medication, and risk of coronary heart disease (CHD) events. METHODS AND RESULTS: Analysis was performed in two prospective cohorts: Whitehall II (WHII; N = 5059) and the British Women's Heart and Health Study (BWHHS; N = 3414). For each participant, scores were calculated based on the cumulative effect of multiple genetic variants influencing total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG). Compared with the bottom quintile, individuals in the top quintile of the LDL-C genetic score distribution had higher LDL-C {mean difference of 0.85 [95% confidence interval, (CI) = 0.76-0.94] and 0.63 [95% CI = 0.50-0.76] mmol/l in WHII and BWHHS, respectively}. They also tended to have greater odds of having 'high-risk' status (Framingham 10-year cardiovascular disease risk >20%) [WHII: odds ratio (OR) = 1.36 (0.93-1.98), BWHHS: OR = 1.49 (1.14-1.94)]; receiving lipid-lowering treatment [WHII: OR = 2.38 (1.57-3.59), BWHHS: OR = 2.24 (1.52-3.29)]; and CHD events [WHII: OR = 1.43 (1.02-2.00), BWHHS: OR = 1.31 (0.99-1.72)]. Similar associations were observed for the TC score in both studies. The TG score was associated with high-risk status and medication use in both studies. Neither HDL nor TG scores were associated with the risk of coronary events. The genetic scores did not improve discrimination over the Framingham risk score. CONCLUSION: At the population level, common SNPs associated with LDL-C and TC contribute to blood lipid variation, cardiovascular risk, use of lipid-lowering medications and coronary events. However, their effects are too small to discriminate future lipid-lowering medication requirements or coronary events.
Authors: Neil M Davies; Frank Windmeijer; Richard M Martin; Mohammad R Abdollahi; George Davey Smith; Debbie A Lawlor; Shah Ebrahim; Ian N M Day Journal: Clin Chem Date: 2011-01-12 Impact factor: 8.327
Authors: Anna Murray; Christie Cluett; Stefania Bandinelli; Anna Maria Corsi; Luigi Ferrucci; Jack Guralnik; Andrew Singleton; Timothy Frayling; David Melzer Journal: Eur Heart J Date: 2009-05-12 Impact factor: 29.983
Authors: Philippa J Talmud; Fotios Drenos; Sonia Shah; Tina Shah; Jutta Palmen; Claudio Verzilli; Tom R Gaunt; Jacky Pallas; Ruth Lovering; Kawah Li; Juan Pablo Casas; Reecha Sofat; Meena Kumari; Santiago Rodriguez; Toby Johnson; Stephen J Newhouse; Anna Dominiczak; Nilesh J Samani; Mark Caulfield; Peter Sever; Alice Stanton; Denis C Shields; Sandosh Padmanabhan; Olle Melander; Claire Hastie; Christian Delles; Shah Ebrahim; Michael G Marmot; George Davey Smith; Debbie A Lawlor; Patricia B Munroe; Ian N Day; Mika Kivimaki; John Whittaker; Steve E Humphries; Aroon D Hingorani Journal: Am J Hum Genet Date: 2009-11 Impact factor: 11.025
Authors: C Baigent; L Blackwell; J Emberson; L E Holland; C Reith; N Bhala; R Peto; E H Barnes; A Keech; J Simes; R Collins Journal: Lancet Date: 2010-11-08 Impact factor: 79.321
Authors: Ardashel Latsuzbaia; Vincent W V Jaddoe; Albert Hofman; Oscar H Franco; Janine F Felix Journal: J Lipid Res Date: 2016-10-24 Impact factor: 5.922
Authors: Laura M Raffield; Amanda J Cox; J Jeffrey Carr; Barry I Freedman; Pamela J Hicks; Carl D Langefeld; Fang-Chi Hsu; Donald W Bowden Journal: Acta Diabetol Date: 2015-02-21 Impact factor: 4.280
Authors: Tibor V Varga; Azra Kurbasic; Mattias Aine; Pontus Eriksson; Ashfaq Ali; George Hindy; Stefan Gustafsson; Jian'an Luan; Dmitry Shungin; Yan Chen; Christina-Alexandra Schulz; Peter M Nilsson; Göran Hallmans; Inês Barroso; Panos Deloukas; Claudia Langenberg; Robert A Scott; Nicholas J Wareham; Lars Lind; Erik Ingelsson; Olle Melander; Marju Orho-Melander; Frida Renström; Paul W Franks Journal: Int J Epidemiol Date: 2017-08-01 Impact factor: 7.196
Authors: Laura M Raffield; Amanda J Cox; Fang-Chi Hsu; Maggie C-Y Ng; Carl D Langefeld; J Jeffrey Carr; Barry I Freedman; Donald W Bowden Journal: Cardiovasc Diabetol Date: 2013-06-25 Impact factor: 9.951